The positive results indicate that the inclusion of VEGF-D and other biomarker studies in future trials may yield new tools for clinical management and contribute to the understanding of disease pathology for TSC and/or LAM. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.